Abhijit G. Banerjee

About

Senior R&D and Strategic planning executive with 30+ years of experience driving translational science, biologics innovation, and product-focused research strategies across oncology and chronic inflammatory diseases. Mentors startups and educational initiatives in Medical Biotechnology for last 16 years.

Employment

• CG BIOMED LLP CSO
  2026 - Present
• Genomic Bio-Medicine Research and Incubation, Chhattisgarh (CGBMRI) Executive Director - Research, Innovations & Incubation, Private Foundation
  2012 - Present
• Ayush & Health Sciences University Chhattisgarh Associate Professor (sabbatical year)
  2010 - 2010
• University of Manitoba Adjunct Professor
  2009 - 2012
• University of Manitoba Faculty of Health Sciences Assistant Professor & Director, Molecular Oncology & Medicine Labs
  2004 - 2009
• University of Nebraska Medical Center College of Medicine Post-doctoral Research Associate (J-1Visiting Scientist)
  2001 - 2004
• Tata Memorial Centre Scientific Officer-D (PB-3)
  1997 - 1999

Education

• Indian Institute of Technology Kharagpur PhD
  1989 - 1995

Projects & Funding

• Intellectual property mobilization on oral cancer targets NSERC
  2009 - 2010
• Oral microbial diseases- Molecular etiology University of Manitoba
  2007 - Present
• Studies on decorin post-transcriptional silencing dependent effects on oral premalignant epithelia Manitoba Health Research Council
  2007 - 2009
• University of Manitoba, Research grants program award University of Manitoba, VP RESEARCH AND DEVELOPMENT
  2005 - 2006
• Role of anti-inflammatory decorin peptides in oral dysplasia and periodontal disease Manitoba Medical Service Foundation
  2005 - 2007
• Molecular Oncology and Medicine Laboratories University of Manitoba, Health Sciences Center
  2004 - Present

Publications (47)

• Glycosaminoglycans and Proteoglycans in Oral Cancer: From Pathobiology to Therapeutic Opportunities
  2026 0 citations DOI: 10.2139/ssrn.6593380
  +Save
• Regulating Epithelial-Mesenchymal Transition and Cancer Metastasis: The Multifaceted Role of Emodin
  2026 0 citations DOI: 10.20944/preprints202604.1592.v1
  +Save
• Therapeutic Potential of Cajanus cajan-Derived Stilbenoids and Flavonoids: From Crop Wastage to Cancer Therapeutics
  2026 0 citations DOI: 10.2139/ssrn.6910358
  +Save
• Synergistic Inhibition of MARCKS-driven Oncogenic Signaling in HNSCC by Emodin and Inositol Hexaphosphate (IP6): A Systems Biology and AI-enhanced Study
  2026 0 citations DOI: 10.2139/ssrn.6286179
  +Save
• Polypharmacological Prospects and Therapeutic Indications of Swertiamarin Scaffolds for Natural Drug Discovery
  2026 0 citations DOI: 10.2139/ssrn.7234920
  +Save
• Oral Microbiome Dysbiosis, MARCKS-Dependent Macrophage Signaling, and Tumor-Associated Macrophages: Emerging Links Between Periodontitis, Systemic Disease, and Carcinogenesis
  2026 0 citations DOI: 10.2139/ssrn.6167307
  +Save
• Leukotriene B4 and the LTA4 Hydrolase Axis in Psoriasis and Atopic Dermatitis: A Convergent Neutrophil-Chemoattractant Node in Chronic Cutaneous Inflammation
  2026 0 citations DOI: 10.2139/ssrn.7568498
  +Save
• Gene Networks in OSCC Across the Logical Progression Cascade, With Neuro-Psychiatric Outcomes: A TCGA Based Network Biology Paradigm
  2026 0 citations DOI: 10.2139/ssrn.6202660
  +Save
• From Pathogens to Tumors: Reframing LAMP–qPCR Translatability as a Unified Diagnostic Paradigm Across Infectious Disease and Oncology <div> - A Perspective </div>
  2026 0 citations DOI: 10.2139/ssrn.6237458
  +Save
• FRZB Prognostic Value in Severe Oral Dysplasia and Head and Neck Squamous Cell Carcinoma: A Computational Genomics Study
  2026 0 citations DOI: 10.2139/ssrn.6229740
  +Save